
FIG. 1A




Mild (score = 1)

FIG. 1B




Moderate (score = 2)

FIG. 1C




Severe (score = 3)

FIG. 2A



None (score = 0)

FIG. 2B




Mild (score = 1)

FIG. 2C




Moderate (score = 2)

FIG. 2D




Severe (score = 3)

FIG. 3A




None (score = 0)

FIG. 3B




Mild (score = 1)

FIG. 3C



Moderate (score = 2)

FIG. 3D



Severe (score = 3)

FIG. 4



Screening
Run-in
Placebo-controlled period (part A)
Long-term treatment (part B)
Safety FU
-4w
-1w
0w
4w
8w
12w
64w
Inclusion criteria
VAS ≥50 mm
EASI ≥10
vIGA ≥3
n = 264
Nemolizumab 0.1 mg/kg Q4W, n = 53
Nemolizumab 0.5 mg/kg Q4W, n = 54
Nemolizumab 2.0 mg/kg Q4W, n = 52
Nemolizumab 2.0 mg/kg Q8W*, n = 52
Nemolizumab 0.1 mg/kg Q4W, n = 41** to 31*
Nemolizumab 0.5 mg/kg Q4W, n = 38** to 28*
Nemolizumab 2.0 mg/kg Q4W, n = 39** to 30*
Nemolizumab 2.0 mg/kg Q8W*, n = 35** to 19*
Patients who meet all criteria are randomized at Day -1 (3:1:1:1:1)
Placebo Q4W, n = 53
(Placebo Rerandomized to active groups)
Nemolizumab 0.1 mg/kg Q4W, n = 13** to 8*
Nemolizumab 0.5 mg/kg Q4W, n = 12** to 7*
Nemolizumab 2.0 mg/kg Q4W, n = 13** to 8*
Emollients
Mild (lowest) TCS/TCI, as needed
No rescue
Rescue (potent TCS)
Rescue (potent/very potent TCS)

FIG. 5



Screening (N = 397)
Randomized (n = 264)
Placebo Q4W (n = 53)
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
Completed Part A (n = 44)
Completed Part A (n = 44)
Completed Part A (n = 45)
Completed Part A (n = 45)
Completed Part A (n = 38)
Transitioned to Part B (n = 41)
Transitioned to Part B (n = 38)
Transitioned to Part B (n = 39)
Transitioned to Part B (n = 35)
Discontinued Part B (n = 10)
• Patient withdrawal (n = 4)
• Lack of efficacy (n = 3)
• Adverse event (n = 2)
• Other (n = 1)
Discontinued Part B (n = 10)
• Patient withdrawal (n = 7)
• Lack of efficacy (n = 2)
• Physician decision (n = 1)
Discontinued Part B (n = 9)
• Patient withdrawal (n = 6)
• Adverse event (n = 1)
• Physician decision (n = 1)
• Other (n = 1)
Discontinued Part B (n = 16)
• Patient withdrawal (n = 6)
• Lack of efficacy (n = 4)
• Adverse event (n = 3)
• Pregnancy (n = 1)
• Lost to follow-up (n = 1)
• Other (n = 1)
Completed Part B (n = 31)
Completed Part B (n = 28)
Completed Part B (n = 30)
Completed Part B (n = 19)
Completed safety follow-up
Nemolizumab 0.1 mg/kg Q4W (n = 48)
Completed safety follow-up
Nemolizumab 0.5 mg/kg Q4W (n = 46)
Completed safety follow-up
Nemolizumab 2.0 mg/kg Q4W (n = 44)
Completed safety follow-up
Nemolizumab 2.0 mg/kg Q8W (n = 39)
Transitioned to Part B
Nemolizumab 0.1 mg/kg Q4W (n = 13)
Transitioned to Part B
Nemolizumab 0.5 mg/kg Q4W (n = 12)
Transitioned to Part B
Nemolizumab 2.0 mg/kg Q4W (n = 13)
Discontinued Part B (n = 5)
• Patient withdrawal (n = 3)
• Adverse event (n = 1)
• Lost to follow-up (n = 1)
Discontinued Part B (n = 5)
• Patient withdrawal (n = 4)
• Protocol violation (n = 1)
Discontinued Part B (n = 5)
• Patient withdrawal (n = 3)
• Lack of efficacy (n = 1)
• Adverse event (n = 1)
Completed Part B (n = 8)
Completed Part B (n = 7)
Completed Part B (n = 8)
Completed safety follow-up without transition to Part B
Placebo Q4W (n = 14)
Completed safety follow-up
Nemolizumab 0.1 mg/kg Q4W (n = 10)
Completed safety follow-up
Nemolizumab 0.5 mg/kg Q4W (n = 10)
Completed safety follow-up
Nemolizumab 2.0 mg/kg Q4W (n = 11)

FIG. 6




A
Change from baseline (%)
0
−20
−40
−60
−80
−100
Part A
Part B
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Weeks
Patient number at each time point
0.1 mg/kg Q4W 53 51 47 45 41 37 37 36 33 32 32 32 32 31 30 29 29
0.5 mg/kg Q4W 54 53 46 45 38 35 34 32 28 30 30 29 29 27 27 26 26
2.0 mg/kg Q4W 52 49 47 46 37 35 32 34 33 31 31 31 29 31 30 30 28
2.0 mg/kg Q8W 52 46 45 39 32 29 28 25 25 23 23 21 19 19 19 19 18
B
Patients (%)
100
90
80
70
60
50
40
30
20
10
0
Part A
Part B
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64
Weeks
Patient number at each time point
0.1 mg/kg Q4W 53 51 47 45 41 37 37 36 33 32 32 32 32 31 30 29 29
0.5 mg/kg Q4W 54 53 46 45 38 35 34 32 28 30 30 29 29 27 27 26 26
2.0 mg/kg Q4W 51 50 48 47 37 35 32 34 33 31 31 31 29 31 30 30 28
2.0 mg/kg Q8W 50 47 45 39 32 29 28 25 25 23 23 21 19 19 19 19 18

FIG. 7


A
Change from baseline (%)
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
Weeks
Patient number at each time point
0.1 mg/kg Q4W 53 51 48 45 40 38 38 38 35 34 34 32 32 31 31 31 31
0.5 mg/kg Q4W 54 53 45 46 38 35 32 31 30 30 30 30 29 27 28 28 28
2.0 mg/kg Q4W 52 50 47 46 38 36 37 34 34 33 32 32 32 32 32 32 29
2.0 mg/kg Q8W 52 46 42 37 34 31 29 27 25 24 22 20 20 19 19 19 19
B
Patients (%)
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
Weeks
Patient number at each time point
0.1 mg/kg Q4W 53 51 48 45 40 38 38 38 35 34 34 32 32 31 31 31 31
0.5 mg/kg Q4W 54 53 45 46 38 35 32 31 30 30 30 30 29 27 28 28 28
2.0 mg/kg Q4W 52 50 47 46 38 36 37 34 34 33 32 32 32 32 32 32 29
2.0 mg/kg Q8W 52 46 42 37 34 31 29 27 25 24 22 20 20 19 19 19 19
C
Change from baseline (%)
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
Weeks
Patient number at each time point
0.1 mg/kg Q4W 53 51 47 45 41 37 37 36 33 32 32 32 32 31 30 29 29
0.5 mg/kg Q4W 54 52 45 44 37 34 33 31 27 29 29 28 28 26 26 26 26
2.0 mg/kg Q4W 52 48 47 46 37 35 32 34 33 31 31 31 31 29 31 30 30 28
2.0 mg/kg Q6W 52 46 45 39 32 29 28 25 25 23 23 21 19 18 19 19 18
D
Patients (%)
Nemolizumab 0.1 mg/kg Q4W (n = 53)
Nemolizumab 0.5 mg/kg Q4W (n = 54)
Nemolizumab 2.0 mg/kg Q4W (n = 52)
Nemolizumab 2.0 mg/kg Q8W (n = 52)
Weeks
Patient number at each time point
0.1 mg/kg Q4W 53 48 46 43 38 36 36 36 36 34 33 33 31 31 30 30 30 30
0.5 mg/kg Q4W 54 50 43 44 36 33 30 29 28 28 28 28 28 26 27 27 27
2.0 mg/kg Q4W 52 49 46 44 37 35 36 33 33 32 31 31 31 31 31 31 31 28
2.0 mg/kg Q8W 52 45 41 37 34 31 28 27 24 24 22 20 20 19 19 19 18